Payton Nyquvest

Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition

Payton Nyquvest On Off-Label Markets

Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network

Payton Nyquvest On Off-Label Markets

Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network

'Sea Change': Irwin Naturals, Numinus And Field Trip Discuss Psychedelics At Cantor Webinar

Numinus Wellness Inc.'s Q4 And Fiscal 2022 Report Shows Revenues Grew 464% To $4.2M

'Sea Change': Irwin Naturals, Numinus And Field Trip Discuss Psychedelics At Cantor Webinar

Numinus Wellness Inc.'s Q4 And Fiscal 2022 Report Shows Revenues Grew 464% To $4.2M

Toronto Residents Get New Ketamine-Assisted Therapy Option Close To Home

Numinus Wellness Announces Q3 Results

Payton Nyquvest Recent News

Numinus Submits New Patent Application To UN Agency For Psilocybe & Novel Fungi Species

Numinus Wellness Inc.

New Acquisition: Numinus To Buy Common Shares Of Novamind Pending Canadian Supreme Court Approval

Numinus Wellness Inc.

Numinus To Acquire Novamind For $20.74M In Stock

Numinus Wellness Reveals 244.5% YoY Improvement In Q1 Revenue & Wider Loss

Numinus Wellness Inc (TSX: NUMI) (OTC: NUMIF) reported its fiscal first-quarter results Thursday for the three months ended Nov. 30, 2021.

Psychedelics Company Numinus Wellness Q4 Revenue Grows 81% YoY Thanks To Mindscape Acquisition

Psychedelics-focused mental health care company Numinus Wellness Inc. (TSXV: NUMI) (OTCQX: NUMIF) announced its fiscal fourth quarter and full-year results Thursday for the periods ended August 31, 2021, with quarterly revenue of CA$500,000 ($394,153) u

What Will The Psychedelics Space Look Like In 2021? Experts Weigh In

In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.

Psyched: MDMA On Health Canada's Radar, MindMed Seeks FDA Support For LSD, Numinus Buys Mindspace

Health Canada Considers MDMA And Psilocybin 'Special Access' Program This week, Health Canada opened a public consultation on its “proposal to restore potential access to restricted drugs through the Special Access Program (SAP).”